Search results for "Pyridones"

showing 7 items of 37 documents

Synthesis, Characterization, and Cu(2+) Coordination Studies of a 3-Hydroxy-4-pyridinone Aza Scorpiand Derivative.

2016

The synthesis, acid-base behavior, and Cu(2+) coordination chemistry of a new ligand (L1) consisting of an azamacrocyclic core appended with a lateral chain containing a 3-hydroxy-2-methyl-4(1H)-pyridinone group have been studied by potentiometry, cyclic voltammetry, and NMR and UV-vis spectroscopy. UV-vis and NMR studies showed that phenolate group was protonated at the highest pH values [log K = 9.72(1)]. Potentiometric studies point out the formation of Cu(2+) complexes of 1:2, 2:2, 4:3, 1:1, and 2:1 Cu(2+)/L1 stoichiometries. UV-vis analysis and electrochemical studies evidence the implication of the pyridinone moieties in the metal coordination of the 1:2 Cu(2+)/L1 complexes. L1 shows …

inorganic chemicalsMagnetic Resonance SpectroscopyStereochemistryPyridinesPyridonesPotentiometric titrationProtonationChemistry Techniques Synthetic010402 general chemistry010403 inorganic & nuclear chemistryElectrochemistryCrystallography X-Ray01 natural sciencesMedicinal chemistryAntioxidantsCoordination complexInorganic Chemistrychemistry.chemical_compoundStructure-Activity RelationshipCoordination ComplexesHumansChelationPhysical and Theoretical ChemistryCell ProliferationChelating Agentschemistry.chemical_classificationLigandHydrogen-Ion Concentration0104 chemical scienceschemistryPotentiometrySpectrophotometry UltravioletCyclic voltammetryDerivative (chemistry)CopperHeLa CellsInorganic chemistry
researchProduct

Treatment of pulmonary embolism.

2015

International audience; The treatment of pulmonary embolism is going to be deeply modified by the development of Direct Oral Anticoagulants (DOACs). There are currently three anti-Xa factors (rivaroxaban, apixaban, edoxaban) and one anti-IIa factor (dabigatran) labeled by the FDA and the EMA. All these drugs are direct anticoagulant, orally effective, without the need for adaptation to hemostasis test. As kidney excretion is involved for all of them, they are contra-indicated in patients with severe renal failure (creatinine clearance<30mL/min according to Cockcroft & Gault formula). All the anti-Xa factor drugs are metabolized by liver cytochromes and then contra-indicated in case of liver…

medicine.drug_classPyridinesPyridones[SDV]Life Sciences [q-bio]PopulationRenal functionRisk AssessmentAntithrombinsDabigatranchemistry.chemical_compoundRivaroxaban[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemEdoxaban[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineHumanseducationeducation.field_of_studyRivaroxabanClinical Trials as Topic[ SDV ] Life Sciences [q-bio]business.industryMedicine (all)AnticoagulantGeneral MedicineVenous Thromboembolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthPulmonary embolismDabigatranThiazolesAntithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Medicine (all)chemistryAnesthesiaPyrazolesApixabanbusinessPulmonary Embolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drugFactor Xa Inhibitors
researchProduct

ROLIPRAM INHIBITS PAF-INDUCED AIRWAY MICROVASCULAR LEAKAGE IN GUINEA-PIG - A COMPARISON WITH MILRINONE AND THEOPHYLLINE

1992

The effects of 3 phosphodiesterase (PDE) inhibitors, rolipram (PDE IV), milrinone (PDE III) and theophylline (non-selective) on PAF (50 ng kg-1; iv)-induced airway vascular leakage have been evaluated in guinea-pigs. Rolipram (3-300 micrograms kg-1; iv) reduced the increase in permeability induced by PAF at all airway levels whereas milrinone (10-1000 micrograms kg-1; iv) and theophylline (30 mg kg-1; iv) were without effects. The anti-leakage activity of rolipram may be of therapeutic value in asthma.

medicine.medical_specialtyPhosphodiesterase InhibitorsPyridonesGuinea PigsRespiratory SystemVascular permeabilityCapillary Permeabilitychemistry.chemical_compoundTheophyllineInternal medicinemedicineAnimalsPharmacology (medical)TheophyllinePlatelet Activating FactorRolipramPharmacologybiologyCyclic nucleotide phosphodiesterasePlatelet-activating factorbusiness.industryPhosphodiesterasePyrrolidinonesEndocrinologychemistryEnzyme inhibitorbiology.proteinMilrinonebusinessRolipramEvans BlueMilrinonemedicine.drug
researchProduct

Iron Chelation Therapy in thalassaemia major: a sistematic review with meta-analyses of 1520 patients included on randomized clinical trials

2011

The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using χ2 (Q) and I2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p<0.0001), increases in serum ferritin levels during DFX 5, 1…

medicine.medical_specialtyPyridonesIronMEDLINEThalassemiaSiderophoresDeferoxamineIron Chelating AgentsChelation treatment thalassaemia clinical trials iron overload meta-analysisBenzoatesGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansVentricular FunctionDeferiproneMolecular BiologyRandomized Controlled Trials as TopicEjection fractionbusiness.industryMyocardiumbeta-ThalassemiaDeferasiroxBeta thalassemiaCell BiologyHematologyTriazolesmedicine.diseaseChelation TherapySurgeryDeferoxamineDeferasiroxTreatment OutcomeLiverchemistryMeta-analysisFerritinsMolecular MedicineDrug Therapy CombinationbusinessDeferipronemedicine.drug
researchProduct

Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.

2020

Background: The comparative efficacy of pirfenidone, nintedanib, and pamrevlumab in slowing the rate of forced vital capacity (FVC) decline and mortality in patients with idiopathic pulmonary fibrosis (IPF) is unknown. Objective: To perform a systematic review and meta-analysis (MA) of these drugs for IPF. Methods: We searched CENTRAL, PubMed, EMBASE, ClincalTrials.gov, and the World Health Organization’s registry databases up to March 2020. Phase II/III randomized controlled trials in adults with IPF were eligible. The random-effect model was implemented calculating the effect size and respective 95% CI as Cohen’s d for change from baseline FVC (in percentage predicted and liters) and odds…

medicine.medical_specialtyVital capacityIndolesPyridones03 medical and health scienceschemistry.chemical_compoundFEV1/FVC ratioIdiopathic pulmonary fibrosis0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)In patient030212 general & internal medicinebusiness.industryPirfenidonemedicine.diseaseIdiopathic Pulmonary FibrosisTreatment Outcome030228 respiratory systemchemistryMeta-analysisNintedanibbusinessAll cause mortalitymedicine.drugThe Annals of pharmacotherapy
researchProduct

New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention

2016

ABSTRACTIntroduction: Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleeding events.Areas covered: In this paper, the authors retrospectively analyzed the relevant literature on the NOACs using the PubMed and Google Scholar databases.Expert commentary: Although warfarin is effective in cardioembolic stroke prevention, easier handling and more favorable risk-benefit profile often render NOACs a more preferable therapy choice for neurologists.…

medicine.medical_specialtyVitamin KPyridonesaspirinmedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyDabigatranAnticoagulation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEdoxabanmedicineHumansatrial fibrillationPharmacology (medical)030212 general & internal medicineIntensive care medicineRivaroxabanAspirinbusiness.industryGeneral Neurosciencenon vitamin-K oral anticoagulantWarfarinAnticoagulantsreverse therapyAtrial fibrillationThrombolysismedicine.diseasemeasure of monitoringStrokewarfarinchemistryAnesthesiaPyrazolesApixabanstroke preventionNeurology (clinical)businessmedicine.drugExpert Review of Neurotherapeutics
researchProduct

Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry

2021

Thrombosis and haemostasis 122(4), 552-559 (2022). doi:10.1055/a-1549-6556

medicine.medical_specialtymedicine.drug_classPyridonesAdministration OralHemorrhagePharmacokineticsRivaroxabanInternal medicineAtrial FibrillationmedicineHumansProspective StudiesRegistriesRivaroxabanbusiness.industryAnticoagulantAnticoagulantsHematologyEmergency situationsConfidence intervalDabigatranClinical trialApixabanObservational studybusinessmedicine.drug
researchProduct